The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Pharmaceutical company Novartis will make its Super Bowl debut with a 60-second spot highlighting breast cancer awareness.